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A B S T R A C T
A clinical study on successful treatment of multifocal brain and spinal cord lesions in neurofibromatosis type 2 in
a woman aged 35 years is presented. Magnetic resonance imaging showed bilateral vestibular schwannomas,
brain meningiomatosis and multiple spinal intramedullary tumours. The treatment comprised four stages: re-
moval of giant dextral vestibular schwannomas, removal of convexital cerebral meningiomatosis, whole-brain
radiation therapy and follow-up. The spinal cord mass was asymptomatic during the entire follow-up. These steps
enabled achievement of a long relapse-free period and resulted in good functional outcomes.
1. Introduction
Neurofibromatosis type 2 (NF2) is a rare, genetically determined,
autosomal dominant disease with an incidence of 1:56,000 and a male-
to-female ratio of 1:1.29 [1]. 22q12 gene damage resulting in merlin
protein tumour suppressor (schwannomin) synthesis causes benign tu-
mour growth in the nervous tissue and skin [2]. NF2 tumour cells have
a higher degree of division and consequently, more intensive growth
than similar masses encountered as independent nosological forms [3].
Bilateral vestibular schwannomas (VS) are a characteristic NF2
feature and the most frequent clinical manifestation.
Treating patients with NF2 is difficult as they are predisposed to
new central nervous system tumour development, making complete
recovery impossible and affecting survival. The overall 5-, 10- and 20-
year survival rate after diagnosis was 85%, 67% and 38%, respectively
[4]. Newer data was obtained in 2015 and was used to estimate the
survival rate of patients with NF2 meningiomatosis following Gamma
Knife radiosurgery (12–14 Gy). Four (33%) of 12 patients died within
the 14-year follow-up. Average age at the time of death was 39 (37–46)
years; average time from the beginning of treatment to death was 103
(93–115) months. Lethality in all cases was caused by meningiomatosis
progression [5].
2. Case presentation
A 35-year-old woman was admitted to the clinic with headaches,
severe dizziness, unsteady walking, right ear hearing loss, impaired left
ear hearing, and weakness in upper and lower extremities.
Her medical history included a progressive decrease in right ear
hearing approximately 3 years ago with follow-up by an ENT specialist.
Impaired left ear hearing and headaches developed 6months pre-
viously. Acute dizziness, unsteady walking and weakness in the ex-
tremities developed 2months ago. As multiple mass lesions were re-
vealed on brain and spinal cord magnetic resonance imaging (MRI), she
was directed to our clinic.
The patient's neurological status was minor right-sided facial nerve
paresis (House–Brackmann Grade II), right-sided deafness, left-sided
hypoacusis, tetraparesis (extremities strength, 4), bilateral pyramidal
insufficiency and expressed coordination deficiency. MRI showed bi-
lateral VS, brain meningiomatosis and multiple spinal intramedullary
tumours.
The right-sided VS was large (42×37×39mm), with an expressed
brainstem and IV ventricle compression, corresponding to the T4b type
according to M. Samii's classification [6]. The left-sided VS was smaller
(10×7×6mm; the T2 type according to M. Samii) (Fig. 1).
Mass lesions with thickened adjacent dura mater were detected on
the right side of the caudal cranial fossa, in posterior horn of left lateral
ventricle, bilaterally in the region of the anterior clinoid processes,
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parasagittally in frontal and parietal regions (bilaterally), on the right
side of the occipital region and in the anterior and middle third of the
cerebral falx. Fig. 2 denotes brain meningiomatosis.
Intramedullary spinal lesions were located in the craniovertebral
junction (C1–C2), C5, C7 and Th1–Th3 (Fig. 3).
The patient underwent audiometry that revealed gross right-side
damage to the auditory analyser down to the level of deafness (78 dB)
and impaired left side function (17 dB).
According to the NIF, NNFF and Manchester criteria, NF2 was di-
agnosed [2,3]. Hereditary history was not aggravated; molecular
Fig. 1. Preoperative MRI, Т1+Gd: Two-sided VSs in a patient with NF2.
(A) Giant right-sided VS. (B) Small left-sided VS. (C) Right-sided caudal cranial fossa meningiomas. (D) Congenital arachnoid cyst of the right temporal lobe.
Fig. 2. MRI, Т1+Gd: Brain meningiomatosis in a patient with NF2.
(A, B) Bilateral meningiomas in the anterior clinoid process and right-sided parasagittal meningioma. (C) Left-sided parasagittal meningioma. (D) Convexital
meningiomatosis. Nodular mass lesions, non-uniform thickening and contrast accumulation in the convexital dura mater. (E, F) Thickened cerebral falx. (G) Right-
sided parasagittal meningioma in the occipital region and right-sided infratentorial meningioma. (H) Meningioma in the posterior horn of the left lateral ventricle.
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genetic studies on NF2 gene mutation were not performed (3).
2.1. Surgery stage I: giant right-sided vestibular schwannoma total excision
Using a standard retrosigmoid approach, the medullocerebellar
cistern was opened and CSF was evacuated to relax the cerebellum. The
OPMI VARIO 700 microscope (Carl Zeiss, Oberkochen, Germany) was
used for tumour removal; facial nerve function was neurophysiologi-
cally monitored using Nim Response 3.0 (Medtronic, Minneapolis, USA)
at all surgery stages. This approach enabled accessible right-sided
caudal cranial fossa meningioma removal. The pathomorphological
response corresponded to neurinoma and grade I fibrotic meningiomas.
2.2. Surgery stage II: convexital brain meningiomatosis removal
4-Month follow-up MRI in the right cerebellopontine angle showed
postoperative changes. There was a significant increase in the signal
intensity and contrast accumulation area because of convexital me-
ningiomatosis and adjacent dura mater. Thickening along the falx and
increased nodular thickening in the inferior part of the anterior and
middle third of the falx were observed with a slight increase in con-
vexital nodular tumour volume.
To evaluate superior sagittal sinus (SSS) permeability and collateral
venous blood flow pathways, total cerebral angiography was per-
formed. Occlusion was detected at the anterior and middle third in-
terface of SSS; the distal occlusion level went beyond the coronary
suture projection by 2 cm. Venous blood outflow occurred through
superficial veins (including the superior anastomotic vein) into the
middle third of SSS and deep cerebral veins.
Wide osteoplastic bifrontal temporal craniotomy was performed;
the frontal parasagittal meningioma, invaded portion of SSS and me-
ningioma of inferior sections of the anterior and middle third of the falx
were removed stepwise. The falx infiltrated with the tumour, anterior
third of SSS and pathologically altered duramater over the right and left
cerebral hemispheres were dissected. SSS was resected until it regained
function. Duraplasty was performed using autogenous tissue (perios-
teum); a pathomorphological study of the altered duramater and nod-
ular lesions (grade I fibrotic psammous meningiomas) was performed.
On day 7 postoperatively, the patient began to develop mental
disorders and expressed frontal ataxia. Follow-up CT and MRI in the
haemorrhaging regions showed no frontal lobe ischaemia.
Abnormalities detected were attributed to cerebral venous blood flow
reorganisation after anterior third of SSS resection and meningioma-
tosis removal.
2.3. Treatment stage III: whole-brain radiation therapy
A tumour board was held at our clinic in which we decided to
conduct a course of remote gamma therapy by irradiating the entire
brain using the Elekta Synergy (Elekta, Stockholm, Sweden) linear ac-
celerator. Such an approach was justified by the sufficiently large area,
number of intracranial regions to be irradiated and more intensive tu-
mour tissue growth due to the genetic nature of the disease.
One month following the second surgery, the patient was irradiated.
The total percentage depth dose was 40 Gr (2 Gr/session). Thus, irra-
diation was applied to mass lesions not subjected to surgery and initial
growth areas of the removed tumours. There were no complications
with the applied irradiation mode.
2.4. Treatment stage IV: follow-up
The first follow-up was performed 6months postoperatively. Her
neurological status still included right facial nerve mild palsy
(House–Brackmann Grade II), right-sided deafness (85 dB), and left-
sided hypoacusia (15 dB), but coordination impairment had regressed.
Follow-up MRI showed no tendency for VS, meningiomas or spinal cord
tumour growth.
We would like to present the 5-year follow-up brain and spinal cord
MRI of the patient (Fig. 4).
Her neurological status remains stable and corresponds to the 6-
month follow-up examination level. We intend to continue with follow-
up.
3. Discussion
The clinical case is of interest regarding treatment tactics for mul-
tifocal extensive lesions in NF2. We faced many issues as there is still no
consensus on multifocal mass lesion treatment in patients with NF2. In
Fig. 3. MRI, Т1+Gd: multifocal spinal cord lesion in a patient with NF2.
(A) Intramedullary lesions (ependymomas) in the craniovertebral junction (C1 vertebra) and intervertebral disc of the Th1-Th2. (B) Intramedullary lesions in the
craniovertebral junction (C1–C2), C5, C7, Th1 and Th2.
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small or medium bilateral VS, tumour removal on the better hearing ear
side is recommended for maintaining higher level of useful hearing on
both sides [6]. However, the right-sided VS in our case was huge and
there was total deafness on that side. Treatment was, thus, initiated
from the right side, primarily to eliminate brainstem compression and
also to preserve useful hearing at the expense of the contralateral ear.
Large VS (diameter > 3 cm) is a direct surgical indication [2]. Radio-
surgery, chemotherapy and expectant management are not reasonable
at this treatment stage.
A 4-month follow-up MRI showed the progress of convexital me-
ningiomatosis, which excluded the possibility of further follow-up and
necessitated a second treatment stage [7]. Targeted therapy in contrast
to the rather good outcome of VS treatment in NF2 was not effective for
meningiomas [8]. Neither was radiotherapy. Previous studies have
demonstrated the applicability of this method; however, the sample
groups had numerous complications and unfavourable outcomes re-
garding survival [5]. Radiotherapy also shows much greater efficiency
in VS treatment [2,3]. Surgery is not devoid of drawbacks either as
evidenced by the patient's postoperative temporary neurological defi-
cits resulting from venous microvasculature reorganisation. It is diffi-
cult to determine whether this or other complications (such as oedema
or venous infarction) occurred during irradiation.
We found no examples of whole-brain radiation therapy for NF2 in
the literature. However, the technique is used for sporadic meningio-
matosis treatment [9]. The irradiation regime employed in this case
targeted the meningiomas and left-sided VS, preventing further tumour
growth.
Based on their radiological characteristics, intramedullary spinal
tumours are ependymomas, which are generally located in cervical and
upper thoracic segments of the spinal cord. As they grow from the
central canal ependyma, they occupy the central part of the spinal cord
and cause its symmetrical expansion. In majority observations, the tu-
mours have asymptomatic progression and are subject to follow-up [3].
Our clinical case was no exception. During the observation period, the
patient showed no signs of compression or intramedullary spinal cord
lesion growth; therefore, we decided to refrain from any manipulation
and performed follow-up.
4. Conclusion
Appropriate multifocal lesion treatment policy selection in NF2 in-
cluding large right-sided VS removal, convexital brain meningiomatosis
removal, whole-brain radiation therapy and follow-up enabled long re-
lapse-free period achievement and ensured good functional outcome.
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